Related Experiment Video

Updated: Jun 15, 2026

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

BRCA1 as a Therapeutic Target in Sporadic Epithelial Ovarian Cancer

Katherine V Clark-Knowles1, Anna M O'Brien, Johanne I Weberpals

  • 1Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, ON, Canada K1H 8L6.

Journal of Oncology
|February 26, 2010
PubMed

Insights

In sporadic epithelial ovarian cancer (EOC), BRCA1 inactivation disrupts DNA repair. Targeting BRCA1 with small molecule inhibitors offers a promising strategy for treating advanced or recurrent EOC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • BRCA1 inactivation is common in sporadic epithelial ovarian cancer (EOC).
  • BRCA1 protein dysfunction impairs critical cellular pathways, including DNA damage response and repair.
  • Defective DNA repair in BRCA1-mutated tumors increases sensitivity to DNA-damaging agents like cisplatin.

Purpose of the Study:

  • To explore BRCA1 as a therapeutic target in sporadic EOC.
  • To review the evolution of BRCA1 as a target for EOC treatment.
  • To outline potential small molecule inhibitors of BRCA1 in EOC.

Main Methods:

  • Review of preclinical and clinical studies on BRCA1 inhibitors.
  • Analysis of BRCA1's role in DNA damage response pathways.
  • Identification of small molecule inhibitors targeting BRCA1.

Main Results:

  • BRCA1 dysfunction is a key event in sporadic EOC pathogenesis.
  • Targeting BRCA1 is a rational therapeutic approach for advanced or recurrent EOC.
  • Several classes of small molecule BRCA1 inhibitors have shown promise in studies.

Conclusions:

  • Inhibiting BRCA1 is an attractive strategy for sporadic EOC treatment.
  • Small molecule inhibitors represent a promising avenue for targeting BRCA1 in EOC.
  • Understanding BRCA1's role is crucial for developing novel EOC therapies.

More Related Videos

In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose13:04

In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose

Published on: October 14, 2015

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...